

*Savas Yayli**Murat Cakir*

Dear colleagues,

After a short interruption, we are delighted to welcome you to the first issue of Mucosa in 2022. We have some changes in this new period. As of this year, Mucosa will be published three issues a year, in January, May and September. We also made some changes in our editorial board, we have new precious members and additional section editors in Pulmonary Medicine, Ophthalmology, Urology and Gynecology. We cordially thank the editorial board members who left us in this new period, and would like to welcome our new members warmly. Mucosa will continue to be a high scientific forum to discuss all aspects of mucosal tissues in different basic and clinical disciplines.

In this issue, we have five scientific articles for you. Yilmaz and Tunali reviewed the effects of mucosal thickness on the marginal bone loss in the implant area from the perspective of periodontology. In the research article section, Uzlu et al investigated the effects of systemic isotretinoin on retinal nerve fiber layer thickness (RNFL) and corneal cell density (CCD). They found decreased RNFL and central corneal thickness by optical coherence tomography.

Kavak et al reported a case series including six female patients with isolated vulvar purpura. They discussed if non-blanching purpura could be a component of plasma cell vulvitis or “mucosal porosis”.

Cowan et al reported a case of bullous pemphigoid (BP) triggered by the Oxford-AstraZeneca Vaxzevria COVID-19 vaccination and it is still one of the first cases of this COVID-19 vaccine-induced BP. Finally, Erat et al reported a rare case of chronic mucocutaneous candidiasis and drew attention to the coexisting endocrinopathies such as vitiligo.

We want to thank our readers, authors, reviewers, and our publisher for their meritorious contributions. We await your valuable contributions to our forthcoming issues in this new period of Mucosa.

Warm regards,

*Murat Cakir*

*Savas Yayli*

Editors-in-Chief